Routine coagulation test abnormalities caused by rivaroxaban
A case report

Zikai Song, PhD, Haidi Wu, MD, Hongyan Cao, MD, Shuo Yang, BA, Minglong Tang, BA, Ling Qin, PhD∗

Abstract

Rationale: Rivaroxaban is a non-vitamin K antagonist oral anticoagulant. Current recommendations state that coagulation monitoring is not required, and neither the dose nor dosing interval requires adjustment in response to changes in coagulation parameters when rivaroxaban is used for approved indications. Guidelines mainly discuss the indications for rivaroxaban and non-vitamin K antagonist oral anticoagulants in general; they offer less guidance regarding how to use these medications in specific clinical situations to bridge the gulf between guidelines and clinical practice.

Patient concerns: An 88-year-old man with a long history of atrial fibrillation presented to the hospital with worsening dyspnea and chest pain. Significantly, he had an estimated glomerular filtration rate of 46.7 mL/min. He was prescribed oral rivaroxaban 20 mg once daily. After 7 days, the patient complained of maroon colored stools.

Diagnosis: Laboratory investigations revealed that the patient’s prothrombin time (PT) and activated partial thromboplastin time (aPTT) were elevated. Rivaroxaban induced gastrointestinal bleeding was suspected.

Interventions: Rivaroxaban was discontinued and routine coagulation tests were monitored daily.

Outcomes: Two days following the discontinuation of the drug, the bleeding was controlled and hemoglobin was normal, but the PT and aPTT remained abnormal. On the third day after discontinuing rivaroxaban, the patient experienced sudden syncope and pulselessness and expired.

Lessons: This case indicates that in real-world situations, a small number of patients may develop changes in both PT and aPTT during rivaroxaban therapy. Therefore, coagulation monitoring should be considered in patients with risk factors for bleeding, such as elderly patients with renal insufficiency.

Keywords: atrial fibrillation, coagulation monitoring, pulmonary embolism, rivaroxaban

1. Introduction

Rivaroxaban is approved for the prevention of stroke in nonvalvular atrial fibrillation (AF),[1] prevention and treatment of venous thromboembolism (VTE),[2] and prophylaxis against deep vein thrombosis (DVT) after knee and hip replacement surgery.[3] It has a predictable anticoagulant effect, eliminating the need for routine coagulation monitoring. Rivaroxaban also has a better efficacy/safety ratio, fewer food and drug interactions, and a more rapid onset of action, compared with vitamin K antagonists. In accordance with current European Society of Cardiology guidelines, rivaroxaban—as a Xa factor inhibitor—should be considered as a first-choice anticoagulant, based on positive results from a number of outcome trials.[1,4] Herein, we report an AF patient combined with pulmonary embolism (PE) and DVT used rivaroxaban 20 mg once daily. But after 7 days, he presented abnormal routine coagulation tests and gastrointestinal bleeding. Despite discontinuing the rivaroxaban, the condition was deterioration and finally died.

2. Case

An 88-year-old man with a long history of AF presented to the hospital with worsening dyspnea and chest pain. On admission, he was fully conscious, with a blood pressure of 110/75 mmHg and an irregular heart rate of 124 bpm on auscultation. He had no edema in either lower limb. The remainder of his physical examination was normal. His oxygen saturation was 90% on room air, his electrocardiogram showed AF, and his transthoracic echocardiogram revealed a left atrial diameter of 43 mm and an ejection fraction of 51%. Lower limb venous compression
ultrasonography showed a DVT involving bilateral superficial femoral veins, the left femoral vein, and the left posterior tibial veins. Laboratory tests revealed normal platelets, hemoglobin, electrolytes, liver function tests, cardiac troponin-T, and routine coagulation tests (prothrombin time [PT] and activated partial thromboplastin time [aPTT]); however, his creatinine, estimated glomerular filtration rate (eGFR), N-terminal pro-brain natriuretic peptide (NT-proBNP), D-dimer level, and arterial blood gases were abnormal (Table 1). Furthermore, computed tomography pulmonary angiography confirmed the presence of an embolus in the right main pulmonary artery and its branch (Fig. 1). To select the appropriate treatment strategy, the congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74, and sex category (female), HAS-BLED= hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly (>65), drugs/alcohol concomitantly, and simplified PE severity index (sPESI) scores were calculated. The scores were 3, 2, and 0, respectively. According to the latest guidelines and the randomized controlled trial study on the use of Non-Vitamin K Antagonist Oral Anticoagulant (NOAC), the patient was prescribed oral rivaroxaban 20mg once daily.[5,6] After 4 days of oral rivaroxaban, the patient’s assays did not change than before oral rivaroxaban (Table 1, Tables 1 and 2). Seven days after the treatment, the patient’s heart rate was lower, dyspnea was relieved, oxygenation was improved, and D-dimer values were lower (Table 1); however, he had maroon stools, and his routine coagulation tests were now abnormal (Table 2).

Table 1

| Physical examination and laboratory results. |
|--------------------------------------------|
| Results | On admission | 4th day after treatment | 7th day after treatment | 2th day after discontinuation | Reference range |
| Heart rate, beats/min | 124 | 90 | 92 | 98 | – |
| eGFR, mL/min | 46.7 | 46.1 | 45.4 | 44.0 | – |
| D-Dimer, pg/mL | >20 | 3.55 | 2.83 | – | <0.50 |
| NT-proBNP, pg/mL | 6223.00 | – | 6491.00 | 6104.00 | <450.00 |
| PaO2, mmHg | 53.1 | 50.5 | 61.1 | 62.0 | 80.0–100.0 |

eGFR=estimated glomerular filtration rate, NT-proBNP=N-terminal pro-brain natriuretic peptide, PaO2=partial pressure of oxygen.

Rivaroxaban was discontinued and routine coagulation tests were monitored daily (Table 2). Two days after discontinuation, the patient had a small amount of maroon stools, normal hemoglobin, and improved NT-proBNP (Table 1), but his routine coagulation tests remained abnormal (Table 2). On the third day after discontinuing rivaroxaban, he experienced sudden syncope and pulselessness. He was treated according to advanced cardiopulmonary life support protocols. After 30minutes, spontaneous circulation was unable to be achieved, and further resuscitation attempts were discontinued. Our case report was waived from the First Hospital of Jilin University Ethical Board, based upon their policy to review all intervention and observational study except for a case report. The patient provided informed consent for the publication of his clinical data. The presented data are anonymized and risk of identification is minimal.

3. Discussion

The combination of AF and VTE (PE and DVT) is not only common and complicated to deal with regarding anticoagulation therapy, but it is also associated with substantial morbidity and mortality. Rivaroxaban is used to prevent ischemic stroke in patients with AF and as prophylaxis and treatment of lower limb DVT and PE.[7] Previous studies have shown that excessive rivaroxaban may cause PT prolongation but has no effect on aPTT.[8] Rivaroxaban can produce concentration-dependent prolongation of PT, and the prolonged PT may provide some quantitative information about the risk of bleeding. It should be noted, however, that prolonged PT can be influenced by many other factors as well, including hepatic impairment and vitamin K deficiency.

Before prescribing rivaroxaban, we followed current recommendations that the indications for anticoagulation be based on a careful risk/benefit analysis.[9] The individual patient’s profile must be considered, including the patient’s age, weight, renal function, liver function, concomitant medications, other comorbidities, and overall frailty. All of these factors may affect the
pharmacokinetics and pharmacodynamics of rivaroxaban.\textsuperscript{10,11} Our patient had clear evidence of AF, PE, and DVT. According to several guidelines, anticoagulant therapy was definitely indicated. Considering his age and moderate renal insufficiency, we prescribed only 20mg orally, but this resulted in gastrointestinal bleeding and significant coagulation abnormalities. We then discontinued the drug, but the patient subsequently developed sudden severe dyspnea and died. Thus, although the patient received 7 days of rivaroxaban and appeared to have a good clinical response, discontinuing the drug resulted in another PE, which was fatal.

Bleeding is a well-known side effect of all anticoagulants, but it is not always associated with elevated concentrations of these drugs. From previous reports of hemorrhage caused by rivaroxaban, only a small number of patients with bleeding treated with a normal dosage had prolonged PT, and none had changes in aPTT. Prolongation of both PT and aPTT was found in only 2 patients consuming large amounts (1960 and 1400mg orally) of rivaroxaban as a method of suicide.\textsuperscript{12,13} Chromogenic anti-factor Xa assays using rivaroxaban calibrators and controls have been shown to accurately measure the anticoagulant effect of rivaroxaban over a wide range of therapeutic levels; however, this assay is not routinely available at most clinical centers.\textsuperscript{14} Lack of access to a readily available laboratory test can be a disadvantage when measurement of anticoagulant effect is clinically relevant, such as within the context of a rivaroxaban overdose.

Most studies and guidelines suggest that the use of rivaroxaban does not require coagulation monitoring. Nevertheless, differences between individuals exist in real-world situations, and not only PT but also aPTT prolongation may occur, especially in elderly adults with renal insufficiency. Clinicians should be aware of patients with an increased risk of bleeding and consider monitoring the coagulation status of these individuals during rivaroxaban therapy.

Acknowledgment
The authors thank all participants for their supports and participation.

Author contributions
Data curation: Shuo Yang, Minglong Tang.
Resources: Shuo Yang, Minglong Tang.
Writing – original draft: Zikai Song.
Writing – review & editing: Ling Qin, Haidi Wu, Hongyan Cao.

References
\begin{enumerate}
\item Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883–91.
\item Investigators E, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499–510.
\item Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2676–73.
\item Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093–104.
\item Steffel J, Verhamme P, Poppara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330–93.
\item Pearson S, Troughton R, Richards AM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:2334–5.
\item Gomez-Outes A, Suarez-Gea ML, Lecumberri R, et al. Rivaroxaban versus enoxaparin for prophylaxis against deep vein thrombosis after total hip arthroplasty. J Thromb Thrombolysis 2015;1:307–15.
\item Doush S, Muller F, Looscn C, et al. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012;130:956–66.
\item Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962.
\item DeWald TA, Becker RC. The pharmacology of novel oral anticoagulants. J Thromb Thrombolyssys 2014;37:217–33.
\item Lehmann T, Hofer KE, Baumann M, et al. Massive human rivaroxaban overdose. Thromb Haemost 2014;112:834–6.
\item Linkins LA, Moffat K. Monitoring the anticoagulant effect after a massive rivaroxaban overdose. J Thromb Haemost 2014;12:1570–1.
\item Lindhoff-Last E, Ansell J, Spiro T, et al. Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. Ann Med 2013;45:423–9.
\end{enumerate}